cyc 202 has been researched along with ciglitazone in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (ciglitazone) | Trials (ciglitazone) | Recent Studies (post-2010) (ciglitazone) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 473 | 0 | 77 |
| Protein | Taxonomy | cyc 202 (IC50) | ciglitazone (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 4.655 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.086 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.22 | |
| Adenosine receptor A3 | Homo sapiens (human) | 3.047 | |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] | Homo sapiens (human) | 2.7 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.047 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.22 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.225 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.047 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
1 other study(ies) available for cyc 202 and ciglitazone
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |